Case studies for therapeutic drug monitoring (TDM)
1 May 2003. Related: Conference reports, PK and drug interactions.
Conference reports
Launch of guide to the use of drug level monitoring
1 May 2003. Related: Conference reports, PK and drug interactions.
10th Conference on Retroviruses and Opportunistic Infections (CROI), 10-14 February 2003, Boston, USA
1 May 2003. Related: Conference reports.
Pharmacokinetic papers from 10th CROI
1 May 2003. Related: Conference reports, PK and drug interactions.
Pediatric studies from 10th CROI
1 May 2003. Related: Conference reports, Women's health, Pregnancy, Paediatric care.
10th Conference on Retroviruses and Opportunistic Infections (CROI), 10-14 February 2003, Boston, USA
1 April 2003. Related: Conference reports.
Pipeline compounds in Phase 2/3 Studies
1 April 2003. Related: Conference reports, Antiretrovirals.
96-week results show tenofovir-including regimen has side-effect advantages over d4T regimen in treatment naïve patients
1 April 2003. Related: Conference reports, Antiretrovirals.
2NN results – nevirapine and efavirenz in prospective randomised head-to-head study
1 April 2003. Related: Conference reports, Antiretrovirals.
NIH/NIAID study of generic drugs shows results consistent with stringent manufacturing standards
1 April 2003. Related: Conference reports, Antiretrovirals, Treatment access, PK and drug interactions.
Treatment interruptions: cycles, pauses, are just plain stopping?
1 April 2003. Related: Conference reports, Antiretrovirals, Treatment strategies.
Conference has strong emphasis on women
1 April 2003. Related: Conference reports, Women's health, Weight, diabetes, metabolic complications, Cancer and HIV.
Tenofovir and renal tubular dysfunction
1 April 2003. Related: Conference reports, Side effects.
Approaches to treatment of lipodystrophy
1 April 2003. Related: Conference reports, Side effects, Weight, diabetes, metabolic complications.
Surgery for buffalo hump shows variable results depending on method
1 April 2003. Related: Conference reports, Side effects, Weight, diabetes, metabolic complications.
Other studies – nucleosides and switching to abacavir; importance of lipoatrophy and buffalo hump
1 April 2003. Related: Conference reports, Side effects, Weight, diabetes, metabolic complications.
HAART to HEART: cardiovascular risk in HIV
1 April 2003. Related: Conference reports, Side effects, Weight, diabetes, metabolic complications.
Alendronate, vitamin D and calcium are safe and effective treatment for HIV-associated bone loss
1 April 2003. Related: Conference reports, Side effects, Weight, diabetes, metabolic complications.
Bone loss and fat loss are closely related in HIV patients on HAART
1 April 2003. Related: Conference reports, Side effects, Weight, diabetes, metabolic complications.
Low dose 200/100 IDV/RTV managed by TDM in substudy of co-infected patients
1 April 2003. Related: Conference reports, PK and drug interactions, Hepatitis coinfection.
12-week response predicts which HIV-HCV coinfected patients will not benefit from continued pegylated interferon plus ribavirin
1 April 2003. Related: Conference reports, Hepatitis coinfection.
Pegylated interferon associated with eye disorders
1 April 2003. Related: Conference reports, Side effects, Hepatitis coinfection.
Nevirapine resistance – the cautionary tales continue
1 April 2003. Related: Conference reports, Pregnancy, Drug resistance.
10th Conference on Retroviruses and Opportunistic Infections, 10-14 February 2003, Boston, USA
1 March 2003. Related: Conference reports.
6th International Congress on Drug Therapy in HIV Infection, 17-21 November 2002, Glasgow, UK
1 February 2003. Related: Conference reports.
Combination of three generic drugs in one pill meets bioequivalence criteria when compared with the branded drugs: Triomune vs d4T/3TC/NVP
1 February 2003. Related: Conference reports, Antiretrovirals, Treatment access.
An overview of the conference
1 February 2003. Related: Conference reports, Antiretrovirals, Weight, diabetes, metabolic complications.
Pharmacokinetic evaluation of tenofovir and enteric-coated ddI
1 February 2003. Related: Conference reports, Antiretrovirals, PK and drug interactions.
The advantages of fosamprenavir; comparing saquinavir/r to lopinavir/r; reducing viral load to <3 copies; AZT-d4T cross resistance; and rising HCV rates
1 February 2003. Related: Conference reports, Antiretrovirals, Treatment strategies, Hepatitis coinfection, Drug resistance.
Promising data regarding DermaVir for therapeutic vaccine
1 February 2003. Related: Conference reports, Basic science and immunology.
Enfuvirtide (T-20): predicting success and modelling survival benefits
1 February 2003. Related: Conference reports, Antiretrovirals, Drug resistance.
Virologic failure among treatment-naive patients taking tenofovir DF or stavudine in combination with lamivudine and efavirenz
1 February 2003. Related: Conference reports, Antiretrovirals.
Comparison of the efficacy and safety of tenofovir vs. d4T when used in combination with 3TC and efavirenz in ARV-naive patients
1 February 2003. Related: Conference reports, Antiretrovirals, Side effects, Weight, diabetes, metabolic complications.
Safety profile of tenofovir in treatment-experienced patients
1 February 2003. Related: Conference reports, Antiretrovirals, Side effects.
42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, 27-30 September 2002
13 November 2002. Related: Conference reports.
Immunology and treatment interruption data presented at the 42nd ICAAC
13 November 2002. Related: Conference reports, Treatment strategies.
Treatment interruptions may result in poor T-cell recovery in patients with nadir CD+ count <50 cells/mm3
13 November 2002. Related: Conference reports, Treatment strategies.
Treatment interruptions are safe in patients with CD4+ count between 300 to 500 cells/mm3 and viral loads lower than 70,000 copies/mL
13 November 2002. Related: Conference reports, Treatment strategies.
Topical transdermal testosterone gel offers significant clinical benefits in hypogonadal HIV-positive patients
13 November 2002. Related: Conference reports, Other news.
BMS experimental PI atazanavir shows potency comparable to NNRTI efavirenz among treatment-naïve HIV patients
13 November 2002. Related: Conference reports, Antiretrovirals.
Adverse drug reactions and lipodystrophy in children
13 November 2002. Related: Conference reports, Paediatric care, Side effects.
Study suggests Kaletra/Combivir is better tolerated PEP than Combivir/nelfinavir
13 November 2002. Related: Conference reports.
Novel approaches to the inhibition of HIV
13 November 2002. Related: Conference reports.
Lipodystrophy and adverse drug reaction data presented at the 42nd ICAAC
13 November 2002. Related: Conference reports, Side effects, Weight, diabetes, metabolic complications.
4th International Workshop on Drug Reactions and Lipodystrophy in HIV Infection, San Diego, 22-25 September 2002
13 November 2002. Related: Conference reports.
Leptin, lipodystrophy and insulin resistance
13 November 2002. Related: Conference reports.
A range of treatments for facial lipoatrophy
13 November 2002. Related: Conference reports, Side effects, Weight, diabetes, metabolic complications.
Autopsy evidence confirms that ARVs tackle CNS lesions
13 November 2002. Related: Conference reports, Basic science and immunology.
XI International HIV Drug Resistance Workshop, Seville, 2-5 July, 2002
11 September 2002. Related: Conference reports.
Short resistance reports from Seville
11 September 2002. Related: Conference reports, Drug resistance.
New anti-HIV compounds discussed at the Seville HIV Drug Resistance Workshop and the Barcelona World AIDS Conference
11 September 2002. Related: Conference reports, Antiretrovirals.
Review of phenotypic resistance testing data presented at the XI International HIV Drug Resistance Workshop
11 September 2002. Related: Conference reports, Drug resistance.
XIV International AIDS Conference Barcelona, 7-12 July 2002
11 September 2002. Related: Conference reports.
Bill Clinton and Nelson Mandela promise to lead peer education among political leaders as world looks for $10 billion a year to fight HIV/AIDS
11 September 2002. Related: Conference reports, Treatment access.
South African activist unveils campaign to force compulsory licences
11 September 2002. Related: Conference reports, Treatment access.
MSF study shows treatment in resource-poor settings is effective
11 September 2002. Related: Conference reports, Treatment access.
‘Barcelona Declaration’ demands 2m poor people are treated in the next two years
11 September 2002. Related: Conference reports, Treatment access.
Lives were lost as experts argued the merits of care versus prevention, says Stefano Vella
11 September 2002. Related: Conference reports, Treatment access.
Peter Piot sets out the global political agenda in the fight against HIV/AIDS
11 September 2002. Related: Conference reports, Treatment access.
Health should be a right, not a commodity, and medicine must be removed from the World Trade Organisation, argues key speaker
11 September 2002. Related: Conference reports, Treatment access.
Governments must act to cut drug prices, says Kenya’s health minister
11 September 2002. Related: Conference reports, Treatment access.
Civil society had to fight for universal access to AIDS drugs in Brazil
11 September 2002. Related: Conference reports, Treatment access.
Coalitions of local NGOs can effectively demand access to medicines, reports MSF
11 September 2002. Related: Conference reports, Treatment access.
Involvement of PLWHA is key to improving access to treatments
11 September 2002. Related: Conference reports, Treatment access.
ART can successfully tackle advanced disease in resource poor settings, reports MSF
11 September 2002. Related: Conference reports, Treatment access.